Abstracts tagged "observation"

Abstract Number: 2666 • 2015 ACR/ARHP Annual Meeting
Trajectories of EQ-5D in RA Patients Treated with Biologics Using the IORRA Cohort
Daisuke Hoshi, Eiichi Tanaka, Eisuke Inoue, Yoko Shimizu, Naoki Sugimoto, Kumi Shidara, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patient-reported outcomes are recognized as important for evaluating the disease status of rheumatoid arthritis (RA). The EuroQol 5-dimensional descriptive system (EQ-5D) has been used…
Abstract Number: 2427 • 2014 ACR/ARHP Annual Meeting
Attainment of Low Disease Activity Is Predictive of Maintenance of Disease Control upon Adalimumab Discontinuation for Two Years Following Combination Therapy in Japanese Patients with Early Rheumatoid Arthritis
Yoshiya Tanaka¹, Hisashi Yamanaka², Naoki Ishiguro³, Nobuyuki Miyasaka⁴, Katsuyoshi Kawana⁵, Katsutoshi Hiramatsu⁶, Aki Kuroki⁵ and Tsutomu Takeuchi⁷, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Abbvie, Tokyo, Japan, ⁶Medical, Abbvie, Tokyo, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Although available data has suggested successful withdrawal of a monoclonal antibody TNF blocker after achieving low disease activity (LDA) or remission over the short-term…
Abstract Number: 110 • 2014 ACR/ARHP Annual Meeting
Use of Smartphones in Collecting Patient Reported Outcomes: Can Passively-Collected Behavior Determine Rheumatic Disease Activity? Early Results from a Nation-Wide Pilot Study
Kaleb Michaud^1,2, Sofia Pedro¹, Rebecca Schumacher¹, Karim Wahba³ and Sai Moturu³, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³ginger.io, San Francisco, CA
Background/Purpose Rheumatoid arthritis (RA) and other rheumatic diseases (RD) are associated with depression, fatigue, and disturbed sleep, symptoms that often impact behavior. Many smartphone apps…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].